Selected Grants
V-INCLUSION
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2024 - 2027Bayer AG - CKD Implementation -Multi-funded
ResearchPrincipal Investigator · Awarded by Bayer HealthCare Pharmaceuticals, Inc · 2024 - 2026Boehringer Ingelheim Pharmaceuticals - CKD Implementation -Multi-funded
ResearchPrincipal Investigator · Awarded by Boehringer Ingelheim Pharmaceuticals, Inc. · 2024 - 2026NOVA-LATAM Lipid Management - Industry
Clinical TrialPrincipal Investigator · Awarded by Novartis Farmaceutica SA de CV · 2022 - 2025Cardio Health Alliance: Test to Treat
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2023 - 2025V-INCLUSION
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2024 - 2027Bayer AG - CKD Implementation -Multi-funded
ResearchPrincipal Investigator · Awarded by Bayer HealthCare Pharmaceuticals, Inc · 2024 - 2026Boehringer Ingelheim Pharmaceuticals - CKD Implementation -Multi-funded
ResearchPrincipal Investigator · Awarded by Boehringer Ingelheim Pharmaceuticals, Inc. · 2024 - 2026NOVA-LATAM Lipid Management - Industry
Clinical TrialPrincipal Investigator · Awarded by Novartis Farmaceutica SA de CV · 2022 - 2025Cardio Health Alliance: Test to Treat
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2023 - 2025A Controlled trial to improve use of High IntEnsity statins for Vascular protEction: ACHIEVE
ResearchCo Investigator · Awarded by National Institutes of Health · 2023 - 2025PCORnet CC - Scope 6 - Playbook
ResearchCo Investigator · Awarded by Patient-Centered Outcomes Research Institute · 2024 - 2025ASCVD EHR Cohort - CardioHealth Alliance Project
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2022 - 2024ESTABLISHING A METABOLIC PLATFORM TO CHARACTERIZE A COHORT AND STREAMLINE TRIALS
ResearchPrincipal Investigator · Awarded by Eli Lilly and Company · 2023 - 2024Impact of a food purchasing intervention on consumption patterns and improved dietary outcomes in New Orleans
ResearchCo Investigator · Awarded by American Heart Association · 2023 - 2024VictORION-Inclusion
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2023 - 2024Landscape Analysis -BI US CKD Study
Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Pharmaceuticals, Inc. · 2022 - 2024BI - CKD PHSR Study
Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Corporation · 2021 - 2024Dissemination and Implementation Science in Cardiovascular Outcomes (DISCO)
Inst. Training Prgm or CMEScholar · Awarded by National Institutes of Health · 2017 - 2024PHENO (BI Heart Failure Implementation Project )
Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Corporation · 2021 - 2024LEADER Trial: Association between weight change and cardiometabolic risk factors in a real-world population of U.S. Adults
Clinical TrialPrincipal Investigator · Awarded by Novo Nordisk, Inc. · 2019 - 2022ATHERO Alliance Learning Lab
ResearchPrincipal Investigator · Awarded by NOVARTIS DE COLOMBIA S.A. · 2022 - 2022Data Characterization of DUHS data for Amgen project
ResearchPrincipal Investigator · Awarded by Amgen, Inc. · 2019 - 2021Characterization of Lp(a) Testing in a Network Consortium
ResearchPrincipal Investigator · Awarded by Amgen, Inc. · 2020 - 2021QuBBD: Deep Poisson Methods for Biomedical Time-to-Event and Longitudinal Data
ResearchInvestigator · Awarded by National Institutes of Health · 2017 - 2021Cardiovascular Risk Profile of LAL Deficiency Patients
ResearchFellow · Awarded by Alexion Pharmaceuticals, Inc. · 2016 - 2020External Relationships
- Alnylam Pharmaceutical, Inc.
- Amgen, Inc.
- AstraZeneca
- Bayer
- Boehringer Ingelheim/Lilly alliance
- Alnylam Pharmaceutical, Inc.
- Amgen, Inc.
- AstraZeneca
- Bayer
- Boehringer Ingelheim/Lilly alliance
- Boehringer Ingleheim
- Esperion
- Janssen Pharmaceuticals (Johnson & Johnson)
- Johnson & Johnson
- Merck
- Miga Health
- Novartis pharmaceuticals
- Novo Nordisk
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.